118 related articles for article (PubMed ID: 23438840)
1. Obesity: Teaching an old drug new tricks--amlexanox targets inflammation to improve metabolic dysfunction.
Koch L
Nat Rev Endocrinol; 2013 Apr; 9(4):185. PubMed ID: 23438840
[No Abstract] [Full Text] [Related]
2. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
3. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes.
Gan X; Wilson MW; Beyett TS; Wen B; Sun D; Larsen SD; Tesmer JJG; Saltiel AR; Showalter HD
J Labelled Comp Radiopharm; 2019 May; 62(5):202-208. PubMed ID: 30828860
[TBL] [Abstract][Full Text] [Related]
5. Amlexanox exerts anti-inflammatory actions by targeting phosphodiesterase 4B in lipopolysaccharide-activated macrophages.
Han Y; Hou R; Zhang X; Liu H; Gao Y; Li X; Qi R; Cai R; Qi Y
Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118766. PubMed ID: 32504661
[TBL] [Abstract][Full Text] [Related]
6. Amlexanox and Forskolin Prevents Isoproterenol-Induced Cardiomyopathy by Subduing Cardiomyocyte Hypertrophy and Maladaptive Inflammatory Responses.
Adzika GK; Hou H; Adekunle AO; Rizvi R; Adzraku SY; Li K; Deng QM; Mprah R; Ndzie Noah ML; Adu-Amankwaah J; Machuki JO; Shang W; Ma T; Koda S; Ma X; Sun H
Front Cell Dev Biol; 2021; 9():719351. PubMed ID: 34631707
[TBL] [Abstract][Full Text] [Related]
7. 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety.
Khandwala A; Van Inwegen RG; Charney MR; Alfano MC
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1997 Feb; 83(2):231-8. PubMed ID: 9117755
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
[TBL] [Abstract][Full Text] [Related]
9. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Beyett TS; Gan X; Reilly SM; Chang L; Gomez AV; Saltiel AR; Showalter HD; Tesmer JJG
Mol Pharmacol; 2018 Oct; 94(4):1210-1219. PubMed ID: 30082428
[TBL] [Abstract][Full Text] [Related]
10. Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.
Zhang Y; Guan H; Li J; Fang Z; Chen W; Li F
Sci Rep; 2015 Sep; 5():13575. PubMed ID: 26338477
[TBL] [Abstract][Full Text] [Related]
11. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
Liu Y; Lu J; Zhang Z; Zhu L; Dong S; Guo G; Li R; Nan Y; Yu K; Zhong Y; Huang Q
Cell Death Dis; 2017 Aug; 8(8):e3022. PubMed ID: 29048430
[TBL] [Abstract][Full Text] [Related]
12. Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation.
Cho CC; Chou RH; Yu C
PLoS One; 2016; 11(8):e0161663. PubMed ID: 27559743
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of amlexanox on carbachol-induced contractions of rabbit ciliary muscle and guinea-pig taenia caecum.
Watanabe N; Tominaga Y; Mizutani K; Ogawa T; Tsunobuchi-Ushijima H; Gomi Y
J Pharm Pharmacol; 2000 Nov; 52(11):1377-85. PubMed ID: 11186246
[TBL] [Abstract][Full Text] [Related]
14. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Qi J; Zhou Z; Lim CW; Kim JW; Kim B
Toxicol Appl Pharmacol; 2019 Dec; 385():114767. PubMed ID: 31697998
[TBL] [Abstract][Full Text] [Related]
15. A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial.
Meng W; Dong Y; Liu J; Wang Z; Zhong X; Chen R; Zhou H; Lin M; Jiang L; Gao F; Xu T; Chen Q; Zeng X
Trials; 2009 May; 10():30. PubMed ID: 19419555
[TBL] [Abstract][Full Text] [Related]
16. Amlexanox for the treatment of recurrent aphthous ulcers.
Bell J
Clin Drug Investig; 2005; 25(9):555-66. PubMed ID: 17532700
[TBL] [Abstract][Full Text] [Related]
17. Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Cruz VH; Arner EN; Wynne KW; Scherer PE; Brekken RA
Mol Metab; 2018 Oct; 16():139-149. PubMed ID: 29935921
[TBL] [Abstract][Full Text] [Related]
18. Amlexanox reversibly inhibits cell migration and proliferation and induces the Src-dependent disassembly of actin stress fibers in vitro.
Landriscina M; Prudovsky I; Mouta Carreira C; Soldi R; Tarantini F; Maciag T
J Biol Chem; 2000 Oct; 275(42):32753-62. PubMed ID: 10921913
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase.
Makino H; Saijo T; Ashida Y; Kuriki H; Maki Y
Int Arch Allergy Appl Immunol; 1987; 82(1):66-71. PubMed ID: 2433225
[TBL] [Abstract][Full Text] [Related]
20. Amlexanox and UPF1 Modulate Wnt Signaling and Apoptosis in HCT-116 Colorectal Cancer Cells.
Bordonaro M; Lazarova D
J Cancer; 2019; 10(2):287-292. PubMed ID: 30719122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
